Around one in 300 women are exposed to GLP-1 medications during pregnancy, according to the American College of Obstetricians and Gynecologists (ACOG). However, the effects of these weight-loss drugs on pregnancy or a developing fetus remain uncertain.
Lawsuits and some studies have raised potential side effects of GLP-1s. In response, ACOG released guidance in late October. They advise patients to discontinue GLP-1 use one to two months before becoming pregnant. Additionally, they recommend careful monitoring of infant neonatal weight gain if mothers use GLP-1s while breastfeeding.
ACOG suggests avoiding GLP-1 medications while breastfeeding preterm infants. Current research does not indicate a high risk of congenital issues due to GLP-1 use before and during pregnancy, but safety data is limited. Studies have not shown the presence of GLP-1s in human milk, although both obesity and malnutrition can impact breast milk composition. ACOG advises discussing a care plan with a physician if using GLP-1s postpartum.
This is a fast-moving area of research, so for now we need to proceed with caution and reassess as more data becomes available,said Yvette LaCoursiere, a professor at the University of California at San Diego and an author of the guidance.
